Neutralizing Interleukin-13 Increases Skin Microbial Diversity: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Tralokinumab in Adult Patients With Atopic Dermatitis. J of Skin 2021, 5 (6), s56. https://doi.org/10.25251/skin.5.supp.56.